181 related articles for article (PubMed ID: 27299695)
21. High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo.
Xu J; Yong M; Li J; Dong X; Yu T; Fu X; Hu L
Oncol Rep; 2015 May; 33(5):2227-34. PubMed ID: 25738998
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the antiproliferative effect of TGFbeta by EGF in primary human ovarian cancer cells.
Dunfield LD; Nachtigal MW
Oncogene; 2003 Jul; 22(30):4745-51. PubMed ID: 12879019
[TBL] [Abstract][Full Text] [Related]
23. [Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo].
Dai L; Liu YX; Xie L; Di W
Zhonghua Fu Chan Ke Za Zhi; 2018 Feb; 53(2):106-110. PubMed ID: 29534379
[No Abstract] [Full Text] [Related]
24. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of TBC1 Domain Family Member 24 (BC1D24) Inhibits Breast Carcinoma Growth via IGF1R/PI3K/AKT Pathway.
Qu X; Zhao B; Hu M; Ji Z; Xu J; Xia W; Qu Y
Med Sci Monit; 2018 Jun; 24():3987-3996. PubMed ID: 29893377
[TBL] [Abstract][Full Text] [Related]
26. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
28. Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.
Carlton AL; Illendula A; Gao Y; Llaneza DC; Boulton A; Shah A; Rajewski RA; Landen CN; Wotton D; Bushweller JH
Gynecol Oncol; 2018 May; 149(2):350-360. PubMed ID: 29551565
[TBL] [Abstract][Full Text] [Related]
29. IGF-I stimulates ERβ and aromatase expression via IGF1R/PI3K/AKT-mediated transcriptional activation in endometriosis.
Zhou Y; Zeng C; Li X; Wu PL; Yin L; Yu XL; Zhou YF; Xue Q
J Mol Med (Berl); 2016 Aug; 94(8):887-97. PubMed ID: 26899323
[TBL] [Abstract][Full Text] [Related]
30. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
31. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
32. Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.
Decollogne S; Joshi S; Chung SA; Luk PP; Yeo RX; Nixdorf S; Fedier A; Heinzelmann-Schwarz V; Hogg PJ; Dilda PJ
Gynecol Oncol; 2015 Aug; 138(2):363-71. PubMed ID: 26080289
[TBL] [Abstract][Full Text] [Related]
33. Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo.
Lu X; Wang L; Mei J; Wang X; Zhu X; Zhang Q; Lv J
Biochem Biophys Res Commun; 2013 Jun; 435(3):385-90. PubMed ID: 23665331
[TBL] [Abstract][Full Text] [Related]
34. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
35. Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.
Guo H; Zhong Y; Jackson AL; Clark LH; Kilgore J; Zhang L; Han J; Sheng X; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Apr; 7(15):20338-56. PubMed ID: 26959121
[TBL] [Abstract][Full Text] [Related]
36. TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells.
Schedlich LJ; Yenson VM; Baxter RC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):56-64. PubMed ID: 23831640
[TBL] [Abstract][Full Text] [Related]
37. Effects of 4-nonylphenol and bisphenol A on stimulation of cell growth via disruption of the transforming growth factor-β signaling pathway in ovarian cancer models.
Park MA; Choi KC
Chem Res Toxicol; 2014 Jan; 27(1):119-28. PubMed ID: 24308608
[TBL] [Abstract][Full Text] [Related]
38. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
39. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
Yamamura S; Matsumura N; Mandai M; Huang Z; Oura T; Baba T; Hamanishi J; Yamaguchi K; Kang HS; Okamoto T; Abiko K; Mori S; Murphy SK; Konishi I
Int J Cancer; 2012 Jan; 130(1):20-8. PubMed ID: 21503873
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
